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Readers could be forgiven for being confused by
the literature on micronutrients and the patho-
genesis of human immunodeficiency virus (HIV)
disease. Micronutrients play important roles in
maintaining immune function and neutralizing
the reactive oxygen intermediates produced by ac-
tivated macrophages and neutrophils in their re-
sponse to microorganisms. Serum and plasma
measurements of vitamins and trace elements,
which are imperfect indicators of body stores, have
shown that deficiencies are common among HIV-
infected persons, especially those who are under-
privileged, such as women in developing coun-
tries, and injection-drug users. A vicious cycle has
been envisaged in which undernourished HIV-
infected persons have micronutrient deficiencies,
leading to further immunosuppression and oxi-
dative stress and subsequent acceleration of HIV
replication and CD4+ T-cell depletion.
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It has been difficult, however, to show causal as-
sociations between specific deficiencies and adverse
clinical outcomes in HIV-infected persons, and data
linking replacement or supplementation of specific
micronutrients with a clinical benefit have been
sparse and inconsistent. In this issue of the 
 
Journal,
 
Fawzi and colleagues report the results of a con-
trolled trial of multivitamin supplementation
among HIV-infected pregnant women in Tanzania.
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Their report prompts important questions about
the plausibility of the findings but also raises broad-
er issues concerning the role of nutrition in the pub-
lic health response to HIV infection and AIDS in Af-
rica in this era of increasing access to antiretroviral
therapy.
The authors compared supplementation consist-
ing of multivitamins alone, vitamin A alone, or both
with placebo. They found that women who were
randomly assigned to receive multivitamin supple-
mentation were less likely to have progression to
advanced stages of HIV disease, had better preser-
vation of CD4+ T-cell counts and lower viral loads,
and had lower HIV-related morbidity and mortality
rates than women who received placebo. Vitamin A
appeared to reduce the effect of multivitamins and,
when given alone, had some negative effects.
The credibility of these data is supported by
sound study design and methods, appropriate
analyses, and compatibility with the limited exist-
ing data, such as those showing decreased mortal-
ity among HIV-infected Thai adults who received
multivitamins.
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 Fawzi and colleagues have previ-
ously shown that multivitamin use is associated
with improved pregnancy outcomes, including re-
duced rates of low birth weight, prematurity, and fe-
tal death.
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 Although some observational data have
associated vitamin A deficiency with increased risks
of perinatal transmission and other adverse out-
comes,
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 vitamin A supplementation has reportedly
been followed by increased rates of mother-to-
child transmission of infection.
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 On the basis of
these previous data as well as the current findings,
there seems to be no justification for pursuing vita-
min A supplementation as an intervention for HIV
infection.
There has been little prior experience with ex-
tensive use of multivitamins in African popula-
tions, and long-term multivitamin administration
has not been considered sustainable. Moreover,
there are no solid data regarding the value of multi-
vitamins among HIV-infected adults in the indus-
trialized world, although routine supplementation
is often practiced. Thus, before definitive recom-
mendations can be made about routine use of
multivitamins in the treatment of persons with HIV
infection and AIDS, there is a clear need to confirm
the new findings and to evaluate the effects of multi-
vitamins in larger populations, particularly among
persons with more advanced HIV disease or more
serious nutritional deficiencies.
As a consequence of the recent substantial in-
crease in funding and support for HIV and AIDS
treatment programs, the treatment options for HIV
disease and AIDS in Africa have changed funda-
mentally since the study under discussion was initi-
ated. Needing to interpret their results against this
altered landscape, Fawzi and colleagues speculate
that by reducing the progression of HIV disease,
the use of multivitamins may delay the need to in-
stitute antiretroviral-drug therapy, thus saving re-
sources as well as preserving therapeutic options.
Individual, small clinical trials rarely form an
adequate basis for policy formulation, and they are
unlikely to answer convincingly the important
questions now raised — specifically, whether multi-
vitamin supplementation can reduce mortality in
the context of increased access to antiretroviral-
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drug therapy and whether the initiation of such
therapy can be delayed. These critical questions
could potentially be answered in Africa by a so-
called large, simple trial.
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 Involving very large pop-
ulations and assessing only hard end points such
as mortality, large, simple trials are especially suit-
able for evaluating simple treatments that probably
have moderate efficacy for common diseases. At a
population level, such treatments can have a con-
siderable effect on public health. Without such a
study, it is unlikely that adequate evidence will be-
come available to provide scientifically based recom-
mendations concerning the use of multivitamin
supplementation for patients with HIV disease and
AIDS and for treatment programs in Africa.
Although definitive policy recommendations
concerning multivitamin supplementation must
await the appropriate evidence (ideally from a large,
simple trial in a population with access to anti-
retroviral drugs), individual treatment programs
and clinicians would be justified in routinely pre-
scribing this nutritional support, since it may pro-
vide a benefit and does no harm. Multivitamins offer
safe opportunities for patients to become accus-
tomed to taking regular medication before begin-
ning antiretroviral therapy. Multivitamins could be
offered through home-based care programs that
until now have too often ignored even basic biomed-
ical interventions such as HIV testing, the need to
rule out tuberculosis, and the provision of trimetho-
prim–sulfamethoxazole to HIV-infected persons.
Fawzi and colleagues’ study of multivitamin sup-
plementation should stimulate broader discussion
of the role of nutrition in patients with AIDS in the
developing world. With its effects on morbidity,
mortality, and poverty, the epidemic of HIV infec-
tion and AIDS has worsened food security in Africa,
especially in the southern part of the continent, the
area most affected by HIV. HIV disease increases
metabolic requirements, suppresses appetite, may
impair swallowing by causing oral and esophageal
opportunistic infections, may be associated with
malabsorption due to various gastroenteropathies,
and perhaps most important, results in progressive
disability and impoverishment, with a consequent
inability to raise or afford food. Undernutrition also
interacts with HIV in a variety of ways. Undernutri-
tion may promote HIV transmission, for example,
when sex is exchanged for money to buy food for
oneself and one’s family. The clinical picture of the
HIV wasting syndrome (also known as the “slim
disease”), a characteristic manifestation of AIDS in
Africa, results in large part from undernutrition in
the face of opportunistic illnesses, especially tuber-
culosis, which itself may be made more likely by
inadequate food intake.
 
8,9
 
 Whatever its cause, a re-
duced body-mass index is a strong predictor of
death.
As donor-funded initiatives expand in Africa, it
has become clear that nutrition will have to be ad-
dressed in the treatment of HIV disease and AIDS.
In the focus-group discussions that we conducted
when starting an antiretroviral treatment program
in a large Nairobi slum, every group interviewed
listed the lack of food as the most likely cause of
nonadherence to antiretroviral (ARV) drug therapy.
One participant succinctly stated, “If you give us
ARVs, please give us food, just food.” There truly is
irony, not captured in the language of treatment ad-
vocacy, in providing antiretroviral drugs to popula-
tions that lack access to safe water or food.
The possibility that a relatively inexpensive inter-
vention such as multivitamin supplementation
could reduce the risk of or delay HIV-associated dis-
ease and death raises the question of how other ba-
sic interventions need to be integrated into our nas-
cent HIV and AIDS treatment programs. Africa’s
health needs extend beyond the treatment of HIV
disease and AIDS; HIV-infected persons are at great
risk from other threats, as well. For example, pro-
grams to prevent mother-to-child transmission of
HIV will not fulfill their potential if ineffective mater-
nal and child health services fail to prevent the many
competing causes of death in women and children.
An obvious approach is the promotion of sim-
ple but important public health interventions along-
side and as part of HIV and AIDS treatment initia-
tives. One example is malaria prevention through
the provision of insecticide-impregnated bed nets.
In western Kenya’s Nyanza Province, an area where
the prevalence of antenatal HIV infection is approx-
imately 25 percent, the provision of insecticide-
treated nets reduced infant mortality by up to 25
percent at a time when no program existed to pre-
vent mother-to-child transmission of HIV.
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 An-
other example is the promotion of point-of-use
chlorination to provide safe drinking water; imple-
mentation of this system reduced the incidence of
diarrhea among HIV-infected adults in Tororo,
Uganda, by 30 percent.
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Innovative schemes will have to be developed to
address the need for food supplementation with-
in HIV and AIDS treatment programs. One such
scheme exists near Eldoret, in western Kenya,
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where a farm has been developed on donated land
and is tended by some of the patients who receive
care at the local clinic. In addition to antiretroviral
drugs, food from the farm can be “prescribed” by
health care providers for HIV-infected patients and
their families.
A final word of caution is required with respect
to the implementation of clinical and public health
measures in Africa. A fine balance is required be-
tween the search for “simple” and “appropriate”
interventions and efforts to institute the effective
measures that we in the industrialized world take
for granted. “Cost-effective” should not be a polite
term for cheap, nor should “simple” mean not very
effective. As attractive and important as simple in-
terventions are and as massive as the shortage of
basic public health infrastructure is, the need for
antiretroviral therapy in Africa is real and compel-
ling. The international community must continue
to expand its efforts to meet this need.
 
The opinions and statements expressed in this article are those of
the authors and do not represent the official policy, endorsement, or
views of the Centers for Disease Control and Prevention, the U.S.
Public Health Service, or the Department of Health and Human Ser-
vices.
 
From the Centers for Disease Control and Prevention, Nairobi,
Kenya.
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